Tommy Fu

2.0k total citations
39 papers, 945 citations indexed

About

Tommy Fu is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Tommy Fu has authored 39 papers receiving a total of 945 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Genetics, 17 papers in Pathology and Forensic Medicine and 17 papers in Oncology. Recurrent topics in Tommy Fu's work include Chronic Lymphocytic Leukemia Research (18 papers), Lymphoma Diagnosis and Treatment (16 papers) and Multiple Myeloma Research and Treatments (11 papers). Tommy Fu is often cited by papers focused on Chronic Lymphocytic Leukemia Research (18 papers), Lymphoma Diagnosis and Treatment (16 papers) and Multiple Myeloma Research and Treatments (11 papers). Tommy Fu collaborates with scholars based in United States, France and Germany. Tommy Fu's co-authors include Johannes Drach, Thomas E. Witzig, André Goy, Sevgi Kalayoğlu Beşışık, Radhakrishnan Ramchandren, Sherri Cicero, Lei Zhang, Michael E. Williams, Rajni Sinha and Aristoteles Giagounidis and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Blood.

In The Last Decade

Tommy Fu

39 papers receiving 927 citations

Peers

Countries citing papers authored by Tommy Fu

Since Specialization

Citations

This map shows the geographic impact of Tommy Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tommy Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tommy Fu more than expected).

Fields of papers citing papers by Tommy Fu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tommy Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tommy Fu. The network helps show where Tommy Fu may publish in the future.

Co-authorship network of co-authors of Tommy Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Tommy Fu. A scholar is included among the top collaborators of Tommy Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tommy Fu. Tommy Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	VARIDT 4.0: distribution variability of drug transporters 2025 ·Nucleic Acids Research ·Yinghong Li, (unknown), (unknown), (unknown), (unknown), (unknown), Hongyin Wang, Qin Xiang, Jiayi Yin, Su Zeng, Tommy Fu, Feng Zhu	1
2	Phase I/II Study of A Novel MDM-2 Inhibitor (APG-115-Alrizomadlin) in p53 Wild Type Salivary Gland Cancers 2024 ·International Journal of Radiation OncologyBiologyPhysics ·Alexander T. Pearson, (unknown), Kedar Kirtane, Emily L. Bellile, Krithika Suresh, (unknown), Francis P. Worden, Christine H. Chung, Everett E. Vokes, J. Chad Brenner, Jonathan B. McHugh, Yifan Zhai, Tommy Fu, Robert Winkler, Paul Swiecicki	2
3	Trial in progress: A phase I/II trial of novel MDM2 inhibitor alrizomadlin (APG-115), with or without platinum chemotherapy, in patients with p53 wild-type salivary gland carcinoma. 2021 ·Journal of Clinical Oncology ·Paul Swiecicki, (unknown), Alexander T. Pearson, Jameel Muzaffar, Mary J. Fidler, Robert Winkler, Tommy Fu, Mingyu Li, Mohammad Ahmad, Dajun Yang, Yifan Zhai	2
4	Trial in Progress: Phase Ib/II Study of Bcl-2/Bcl-Xl Inhibitor Pelcitoclax (APG-1252) in Patients with Myelofibrosis (MF) That Progressed after Initial Therapy 2020 ·Blood ·Naveen Pemmaraju, Boyd Mudenda, Cunlin Wang, Jiao Ji, Ming Lü, Tommy Fu, (unknown), (unknown), (unknown), Srđan Verstovšek, (unknown), Yifan Zhai	4
5	The distribution of cardiac diagnostic testing for acute coronary syndrome in the Brazilian healthcare system: A national geospatial evaluation of health access 2019 ·PLoS ONE ·Julian T. Hertz, Tommy Fu, João Ricardo Nickenig Vissoci, Thiago Augusto Hernándes Rocha, (unknown), Brendan Flanagan, Luciano de Andrade, Alexander T. Limkakeng, Catherine A. Staton	10
6	Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials 2018 ·Annals of Oncology ·Matthew J. Maurer, Thomas M. Habermann, Qian Shi, Norbert Schmitz, David Cunningham, Michael Pfreundschuh, John F. Seymour, Ulrich Jaeger, Corinne Haïoun, Hervé Tilly, Hervé Ghesquières, Francesco Merli, Marita Ziepert, Raoul Herbrecht, Jocelyne Flament, Tommy Fu, Christopher R. Flowers, Bertrand Coiffier	47
7	Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient–Level Analysis of Multiple Randomized Trials (SEAL) 2018 ·Journal of Clinical Oncology ·Qian Shi, Norbert Schmitz, Fang‐Shu Ou, Jesse G. Dixon, David Cunningham, Michael Pfreundschuh, John F. Seymour, Ulrich Jaeger, Thomas M. Habermann, Corinne Haïoun, Hervé Tilly, Hervé Ghesquières, Francesco Merli, Marita Ziepert, Raoul Herbrecht, Jocelyne Flament, Tommy Fu, Bertrand Coiffier, Christopher R. Flowers	47
8	Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients 2016 ·Blood ·Matthew J. Maurer, Thomas M. Habermann, Qian Shi, Norbert Schmitz, David Cunningham, Michael Pfreundschuh, John F. Seymour, Ulrich Jaeger, Corinne Haïoun, Hervé Tilly, Hervé Ghesquières, Francesco Merli, Marita Ziepert, Raoul Herbrecht, Jocelyne Flament, Tommy Fu, Christopher R. Flowers, Fang‐Shu Ou, Daniel J. Sargent, Bertrand Coiffier	5
9	115 MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS EPO ON RBC TRANSFUSION INDEPENDENCE (RBC-TI) IN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MDS WITHOUT DEL(5Q) 2015 ·Leukemia Research ·Valeria Santini, (unknown), Arlene S. Swern, (unknown), Aristoteles Giagounidis, Tommy Fu, Albert Hoenekopp, C.L. Beach, B. Skikne, Pierre Fenaux	3
10	Information security awareness and behaviour: of trained and untrained home users in Sweden. 2015 ·KTH Publication Database DiVA (KTH Royal Institute of Technology) ·(unknown), Tommy Fu	6
11	p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q) 2014 ·Haematologica ·Leonie Saft, Masoud Karimi, Mehran Ghaderi, András Matolcsy, G J Mufti, Austin Kulasekararaj, Gudrun Göhring, Aristoteles Giagounidis, Dominik Selleslag, Petra Muus, Guillermo Sanz, Moshe Mittelman, David Bowen, Anna Porwit, Tommy Fu, Jay T. Backstrom, (unknown), Kyle J. MacBeth, Eva Hellström‐Lindberg	97
12	Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS 2013 ·Leukemia ·(unknown), Alan F. List, John M. Bennett, Mikkael A. Sekeres, B. Skikne, Tommy Fu, Jamile M. Shammo, Stephen D. Nimer, Robert Knight, Aristoteles Giagounidis	73
13	Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study 2013 ·Journal of Clinical Oncology ·André Goy, Rajni Sinha, Michael E. Williams, Sevgi Kalayoğlu Beşışık, Johannes Drach, Radhakrishnan Ramchandren, Lei Zhang, Sherri Cicero, Tommy Fu, Thomas E. Witzig	264
14	Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study. 2013 ·Journal of Clinical Oncology ·Michael E. Williams, André Goy, Rajni Sinha, Sevgi Kalayoğlu Beşışık, Johannes Drach, (unknown), Lei Zhang, Sherri Cicero, Tommy Fu, Thomas E. Witzig	3
15	Polyps With Advanced Neoplasia Are Smaller in the Right Than in the Left Colon: Implications for Colorectal Cancer Screening 2012 ·Clinical Gastroenterology and Hepatology ·Samir Gupta, Bijal A. Balasubramanian, Tommy Fu, Robert M. Genta, Don C. Rockey, Richard H. Lash	60
16	58 Interaction of karyotype complexity and response on overall survival and AML progression in lenalidomide-treated Low/INT-1 risk del (5q) MDS patients 2011 ·Leukemia Research ·Aristoteles Giagounidis, Eva Hellström‐Lindberg, Pierre Fenaux, Jay T. Backstrom, Tommy Fu, Alan F. List	2
17	Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High-Dose Dexamethasone 2009 ·Journal of Clinical Oncology ·Maurizio Zangari, Guido Tricot, (unknown), Fenghuang Zhan, (unknown), Robert Knight, Tommy Fu, Donna Weber, Meletios Α. Dimopoulos, Rubén Niesvizky, Louis M. Fink	44
18	RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004). 2009 ·Blood ·Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, Odile Beyne‐Rauzy, Ghulam J. Mufti, Moshe Mittelman, Petra Muus, Peter A.W. te Boekhorst, Guillermo Sanz, Consuelo del Cañizo, Agnès Guerci‐Bresler, Brigitte Schlegelberger, Carlo Aul, Hans Kreipe, Gudrun Goehring, Robert Knight, John Francis, Tommy Fu, Eva Hellström‐Lindberg	19
19	Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma Were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status 2008 ·Blood ·Asher Chanan‐Khan, Meletios Α. Dimopoulos, Donna M. Weber, Andrew Spencer, Michel Attal, Andrew Belch, Alessandro Corso, Tommy Fu, Jerome B. Zeldis, Marta Olesnyckyj, Robert Knight, Sagar Lonial	5
20	Impact of Age on Transfusion Independence Response, Survival, and Transformation to Acute Myeloid Leukemia in Patients with Deletion 5q: A Sub-Analysis of the MDS-003 Study 2008 ·Blood ·Minoo Battiwalla, Tommy Fu, Robert Knight, Alan F. List	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact